SEARCH

SEARCH BY CITATION

References

  • 1
    Tandon R, Keshavan MS, Nasrallah HA. Schizophrenia, ‘just the facts’ what we know in 2008. 2. Epidemiology and etiology. Schizophr Res 2008; 102: 118.
  • 2
    Tandon R, Keshavan MS, Nasrallah HA. Schizophrenia, ‘Just the Facts’: what we know in 2008 part 1: overview. Schizophr Res 2008; 100: 419.
  • 3
    Faber G, Smid HG, Van Gool AR, Wunderink L, Wiersma D, van den Bosch RJ. Neurocognition and recovery in first episode psychosis. Psychiatry Res 2011; 188: 16.
  • 4
    Jeppesen P, Petersen L, Thorup A et al. The association between pre-morbid adjustment, duration of untreated psychosis and outcome in first-episode psychosis. Psychol Med 2008; 38: 11571166.
  • 5
    Malla AK, Bodnar M, Joober R, Lepage M. Duration of untreated psychosis is associated with orbital-frontal grey matter volume reductions in first episode psychosis. Schizophr Res 2011; 125: 1320.
  • 6
    Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry 2005; 62: 975983.
  • 7
    Alvarez-Jimenez M, Gleeson JF, Henry LP et al. Prediction of a single psychotic episode: a 7.5-year, prospective study in first-episode psychosis. Schizophr Res 2011; 125: 236246.
  • 8
    White C, Stirling J, Hopkins R et al. Predictors of 10-year outcome of first-episode psychosis. Psychol Med 2009; 39: 14471456.
  • 9
    Case M, Stauffer VL, Ascher-Svanum H et al. The heterogeneity of antipsychotic response in the treatment of schizophrenia. Poster presented at the SIRS (Schizophrenia International Research Society) Congress at Florence, Italy, 10–14 April, 2010.
  • 10
    Lieberman JA, Koreen AR, Chakos M et al. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry 1996; 57 (Suppl. 9): s59.
  • 11
    Robinson D, Woerner MG, Alvir JM et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999; 56: 241247.
  • 12
    Wiersma D, Nienhuis FJ, Slooff CJ, Giel R. Natural course of schizophrenic disorders: a 15-year follow-up of a Dutch incidence cohort. Schizophr Bull 1998; 24: 7585.
  • 13
    Velligan DI, Weiden PJ, Sajatovic M et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 2009; 70 (Suppl. 4): s146.
  • 14
    Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S. Oral versus depot antipsychotic drugs for schizophrenia-A critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res 2011; 127: 8392.
  • 15
    Carswell C, Wheeler A, Vanderpyl J, Robinson E. Comparative effectiveness of long-acting risperidone in New Zealand: a report of resource utilization and costs in a 12-month mirror-image analysis. Clin Drug Investig 2010; 30: 777787.
  • 16
    Olivares JM, Peuskens J, Pecenak J et al. Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry. Curr Med Res Opin 2009; 25: 21972206.
  • 17
    Peuskens J, Olivares JM, Pecenak J et al. Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries. Curr Med Res Opin 2010; 26: 501509.
  • 18
    Peuskens J, Mertens C, Kusters J et al. Long-acting Risperidone in the treatment of schizophrenia: data from a 24-month Belgian electronic Schizophrenia Treatment Adherence Registry (e-STAR). Acta Psychiatr Belg 2010; 110: 3446.
  • 19
    Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection. Int Clin Psychopharmacol 2008; 23: 325331.
  • 20
    Kim B, Lee SH, Choi TK et al. Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 12311235.
  • 21
    Weiden PJ, Schooler NR, Weedon JC, Elmouchtari A, Sunakawa A, Goldfinger SM. A randomized controlled trial of long-acting injectable risperidone versus continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome. J Clin Psychiatry 2009; 70: 13971406.
  • 22
    Dubois V, Megens J, Geerts P. Long-acting risperidone in early-episode schizophrenia. Acta Psychiatr Belg 2011; 111: 921.
  • 23
    Peuskens J, Dubois V, Geerts P, Detraux J. Clinical outcomes of long-acting risperidone in recent versus long-term diagnosed Belgian schizophrenic patients: results from e-STAR (Electronic Schizophrenia Treatment Adherence Registry). Poster presented at the 7th International Conference on Early Psychosis, 28 November–1 December, 2010, Amsterdam, The Netherlands.
  • 24
    American Psychiatric Association. DSM-IV®-TR. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: Author, 2003.
  • 25
    De Rick K, Van Audenhove C, Lammertyn F. De omvang van de groep van ernstig en langdurig psychisch zieken. Tijdschr voor Geneeskunde 2002; 58: 729735.
  • 26
    Van Audenhove C, Van Humbeeck G, Van Meerbeeck A. De vermaatschappelijking van de zorg voor psychisch kwetsbare mensen. Onderzoek, praktijk en beleid. LannooCampus, Leuven; 2005.
  • 27
    Csernansky JG, Mahmoud R, Brenner R. Risperidone-USA-79 Study Group. N Engl J Med 2002; 346: 1622.
  • 28
    Haro JM, Kamath SA, Ochoa S et al. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand 2003; 416: s1623.
  • 29
    Haro JM, Edgell ET, Novick D et al. Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study. Acta Psychiatr Scand 2005; 111: 220231.
  • 30
    Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005; 162: 441449.
  • 31
    McEvoy JP, Lieberman JA, Stroup TS et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006; 163: 600610.
  • 32
    Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 12091223.
  • 33
    Stroup TS, Lieberman JA, McEvoy JP et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006; 163: 611622.
  • 34
    Kahn RS, Fleischhacker WW, Boter H et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008; 371: 10851097.
  • 35
    McEvoy JP, Lieberman JA, Perkins DO et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007; 164: 10501060.
  • 36
    Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Clin Ther 2008; 30: 23782386.
  • 37
    Christensen TB, Kissling WK, Lex A et al. Direct switching to risperidone long-acting injectable: experience in patients early in the course of the disease. Int J Neuropsychopharmacol 2004; 7 (Suppl. 2): s236237.
  • 38
    Christensen TB, Kissling WK, Medori R. Long-acting risperidone in patients with early psychosis – less than 1 year duration. Poster presented at the World Psychiatric Association (WPA) International Congress, Istanbul, Turkey, 12–16 July, 2006.
  • 39
    Napryeyenko O, Burba B, Martinez G et al. Efficacy and tolerability among patients with recent-onset schizophrenia treated with long-acting injectable risperidone (RLAI). Poster presented at the 9th World Congress of Biological Psychiatry (WCBP), Paris, France, June 28–July 2, 2009.
  • 40
    Parellada E, Andrezina R, Milanova V et al. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable. J Psychopharmacol 2005; 19 (Suppl 5): s514.
  • 41
    Parellada E, Kouniakis F, Siurkute A, Schreiner A, Don L. Safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disorders. Int Clin Psychopharmacol 2010; 5: 149154.
  • 42
    Saleem PT, Firmino H, Psiquiatria S, Parellada E, Schreiner A, Möller H-J. Young patients (18–30 years) with schizophrenia and schizoaffective disorder: results of direct switching to long-acting injectable risperidone (StoRMi trial). Poster presented at the twelfth winter workshop on schizophrenia, Davos, Switzerland, 7–13 February, 2004.
  • 43
    Macfadden W, Bossie C, Turkoz I et al. Effect of long-acting injectable risperidone on clinical outcomes in recently diagnosed, stable schizophrenia patients. Poster presented at the 60th Annual Meeting of the American Psychiatric Association (APA), Institute on Psychiatric Services (IPS), Chicago, Illinois, USA, 2–5 October, 2008.